Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Development of Novel Neutralizing Single-Chain Fragment Variable Antibodies Against S100a8 Publisher Pubmed



Raeisi H1 ; Azimirad M1 ; Schiopu A2 ; Zarnani AH3 ; Asadzadeh Aghdaei H4 ; Abdemohamadi E1 ; Zali MR5 ; Yadegar A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Translational Medicine, Lund University, Lund, Sweden
  3. 3. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Scientific Reports Published:2025


Abstract

S100A8 plays a critical role in the pathogenesis of several inflammatory diseases and multiple types of cancer. Therefore, targeting the S100A8 function may alleviate the pathogenic process in various diseases. Here, specific single-chain variable fragment (scFv) antibodies targeting recombinant S100A8 (rS100A8) were selected by phage display technique and characterized using cDNA sequencing, immunoassay tests, and molecular docking. The neutralizing activity of scFvs was examined by a cell viability assay in rS100A8-treated macrophages. Furthermore, the modulatory effects of scFvs on the expression of inflammatory markers and apoptosis-related genes in macrophages and human colorectal carcinoma HT-29 cells treated with rS100A8 or dextran sulfate sodium (DSS) were assessed by RT-qPCR and flow cytometry. Based on our results, four scFvs were identified to be capable of detecting rS100A8 in the immunoassay tests. Among the selected scFvs, two clones (SA8-E6 and SA8-E12), alone or in combination, exhibited the highest blocking activity on rS100A8 and potently inhibited S100A8-induced cytotoxicity in macrophages. The use of a SA8-E6 and SA8-E12 (SA8-E6-12) cocktail inhibited the upregulation of TLR4 and RAGE, as well as inflammation and apoptosis-related genes in macrophages and HT-29 cells stimulated with rS100A8. Additionally, SA8-E6-12 exerted a significant inhibitory effect on inflammation and apoptosis induced by the S100A8/A9 complex in DSS-stimulated macrophages. We also demonstrated by molecular docking that the interaction of S100A8 with SA8-E6-12 was mainly restricted to the binding domain involved in the connection of S100A8 to TLR4. Further studies are required to explore the efficacy of these anti-S100A8 scFvs as potential therapeutic agents using in vivo models of S100A8-driven inflammatory diseases. © The Author(s) 2025.
Related Docs
1. Development and Characterization of Phage Display-Derived Anti-Toxin Antibodies Neutralizing Tcda and Tcdb of Clostridioides Difficile, Microbiology Spectrum (2023)
2. Circulating Levels of Calprotectin As a Biomarker in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis, Clinical Cardiology (2024)
3. An Overview on Display Systems (Phage, Bacterial, and Yeast Display) for Production of Anticancer Antibodies; Advantages and Disadvantages, International Journal of Biological Macromolecules (2022)
4. Differential Expression of Neurodegeneration-Related Genes in Sh-Sy5y Neuroblastoma Cells Under the Influence of Cyclophilin A: Could the Enzyme Be a Likely Trigger and Therapeutic Target for Alzheimer’S Disease?, Neurochemical Research (2025)
Experts (# of related papers)
Amirhasan Zarnani (1)